News
Publications
HSC-engineered CAR-iNKT cells, generated using a clinically guided culture method, provide a promising platform for off-the-shelf cancer cell therapy
The first-in-human clinical trial of “off-the-shelf”, allogeneic CAR-NKTs indicate that these cells are well tolerated and can mediate objective responses in relapsed or refractory NHL and ALL patients even at low doses.
Cellular therapy using off-the-shelf iNKT cells is safe, can be rapidly scaled and is associated with an anti-inflammatory response in ARDS patients
A novel therapeutic strategy utilizing off-the-shelf iNKT cells shows potential for enhancing antitumor immunity in PD-1 refractory tumors and overcoming resistance to checkpoint inhibitors
Donor-specific iNKT biomarkers of survival and sustained functionality, which are conserved in dogs and humans and retained upon CAR-engineering, correlate with extended persistence in immunocompetent, MHC-mismatched canine recipients
Autologous GD2-specific CAR NKT cells co-expressing an interleukin 15 transgene (GD2-CAR.15) exhibited a safe profile in 12 children with neuroblastoma. Two partial responses and one complete response were observed.
CAR-iNKT cells are a powerful anti-tumor therapy, that is further enhanced by combination with checkpoint inhibitors, and can potentially reduce the risk of GVHD after allogeneic hematopoietic stem cell transplantation
CAR iNKT cells induce host CD8 T-cell antitumor responses
Anti-TCRVβ CAR T and CAR iNKT cells show promise for treating T Cell Lymphomas, with CAR iNKTs from healthy donors providing a safe and valuable 'off-the-shelf' option
First in-human study to characterize human iNKT cell heterogeneity and subsets at the thymic level